Abstract 4541
Background
Patients (pts) with advanced cancer have high rates of healthcare resource utilization at the end of life (EOL). Immunotherapy (IO) has changed the treatment landscape for many patients with cancer. The impact of IO on resource utilization at the EOL for pts with metastatic disease, including emergency department (ED) visits, hospitalizations, and referrals to hospice is unknown.
Methods
We conducted a single center, retrospective analysis of pts treated with PD-1/L1 or CTLA-4 antibodies alone or in combination from 2011 – 2017. We identified 1,113 pts from electronic health records and present here clinical information for 306 pts with metastatic disease and end of life outcome data for 188 decedents. Survival curves were compared using log-rank test for pts by disease, treatment type, ECOG performance status (PS) at treatment start, and age. Hospice referral rate was compared using Fisher’s exact test.
Results
Of the 306 pts, 131 (43%) had melanoma, 42 (14%) had renal cell carcinoma, 33 (11%) had non-small cell lung cancer, 22 (7%) had head and neck carcinoma, and 78 (25%) had another advanced malignancy. Treatment consisted of nivolumab in 130 (42%) pts, ipilimumab in 73 (24%), pembrolizumab in 59 (19%), nivolumab/ipilimumab in 23 (8%), atezolizumab in 9 (3%), and other IO combinations in 12 (4%). Of the 188 (61%) pts who died, 93 (49%) had at least one ED visit in the last month of life, 110 (59%) had at least one hospitalization, and 21 (11%) died in the hospital. Of all pts who died, 156 (83%) had hospice referral with a median of 11 days (range 1-420) between hospice referral and death. Overall survival (OS) was not associated with disease type (p = 0.11) or treatment (p = 0.832), but was associated with ECOG PS (p = 0.013). Referral to hospice did not vary by disease type (p = 0.945), treatment type, (p = 0.809) or age (p = 0.432), but did vary by ECOG PS (p = 0.006). Death within 72 hours of hospice referral rate varied significantly by inpatient or outpatient referral (p = 0.002).
Conclusions
Hospitalizations and ED visits are frequent at the EOL among pts who received IO for advanced malignancies. There was a high referral rate to hospice, but the median time between hospice referral and death was short. Interventions to decrease aggressive EOL care are needed.
Clinical trial identification
Legal entity responsible for the study
Jarred Burkart.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
A.M. Noonan: Paid member of a data safety monitoring board from 2016-2017: Helsinn. All other authors have declared no conflicts of interest.
Resources from the same session
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.
Presenter: Guek Eng Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers
Presenter: Agnese Losurdo
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4755 - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer
Presenter: Chihwan Cha
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2741 - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
Presenter: Anees Hassan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3356 - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Presenter: Da Young Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4020 - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
Presenter: Yan Xu
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers
Presenter: Elodie Klajer
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4516 - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy
Presenter: Nawale Hajjaji
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract